Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Analizzato: 2026-05-13Prossimo aggiornamento: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Prezzo
$725.17
▲ +290.95 (+40.12%)
Valore equo
$1016
$737–$1308
Valutazione
Acquisto forte
confidence 79/100
Potenziale rialzo
+40.1%
upside to fair value
Margine di Sicurezza
$863.70
MoS level · 15%
Capitalizzazione
$87.2B
P/E fwd 14.4
Fallback in ingleseIT
Mostrando la fonte in inglese mentre traduciamo
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.

§1 Sintesi

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Scenario ribassista

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Come questa tesi può fallire

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
Segnali di allerta precoce da monitorare
MetricaAttualeSoglia di attivazione
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Storia finanziaria

Conto economico — ultimi sei periodi
VoceT−0T−1T−2T−3CAGR
Periodo2022-03-312023-03-312024-03-312025-03-31Trend
Ricavi$263.97B$276.71B$308.95B$359.05B+10.8%
Utile lordo$13.13B$12.36B$12.83B$13.32B+0.5%
Reddito operativo$2.59B$4.58B$4.17B$4.82B+22.9%
Utile netto$1.11B$3.56B$3.00B$3.30B+43.5%
EPS (diluito)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
R&S
SG&A$10.54B$7.78B$8.66B$8.51B-6.9%

Punteggi di qualità

OCF / Utile netto
1.85×
>1 indica alta qualità degli utili
Soglia di qualità contabile
Fail
Soglia corretta per settore
ROIC
68.7%
Rendimento del capitale investito
Sezione 3

Numbers analysis

Flusso di cassa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Allocazione del capitale

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abbonati individuali — da §4 in poi11 sezioni in più

Leggi l'analisi completa — 11 sezioni in più.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Report completo per ogni ticker coperto
24 mesi di archivio rating
Briefing della watchlist + avvisi di variazione del rating
Esportazione PDF + DOCX in qualsiasi lingua
Inizia la prova gratuita
Annulla in qualsiasi momento.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder